ONCOR PRICING INFORM HER-2/NEU BREAST CANCER RECURRENCE TEST AT $100; FIRST QUARTER LAUNCH ANTICIPATED FOLLOWING DEC. 30 PMA APPROVAL
This article was originally published in The Gray Sheet
Oncor plans to offer its Inform HER-2/neu gene-based DNA test for predicting recurrence of breast cancer at a price of about $100 per determination to qualified testing laboratories following roll-out in the first quarter of 1998.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.